Literature DB >> 26292310

Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.

Michael G Whitfield1, Robin M Warren2, Elizabeth M Streicher1, Samantha L Sampson1, Frik A Sirgel1, Paul D van Helden1, Alexandra Mercante3, Melisa Willby3, Kelsey Hughes3, Kris Birkness3, Glenn Morlock3, Annelies van Rie4, James E Posey3.   

Abstract

Sequencing of the Mycobacterium tuberculosis pncA gene allows for pyrazinamide susceptibility testing. We summarize data on pncA polymorphisms that do not confer resistance at a susceptibility breakpoint of 100 μg/ml pyrazinamide in MGIT within a cohort of isolates from South Africa and the U.S. Centers for Disease Control and Prevention.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26292310      PMCID： PMC4609709          DOI： 10.1128/JCM.01001-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the radiometric Bactec 460TB system.

Authors:  Fanourios Kontos; Stavroula Nicolaou; Christos Kostopoulos; Zoe Gitti; Efthymia Petinaki; Maria Maniati; Spyridoula Anagnostou; Aikaterini Raftopoulou; Panagiota Papageorgiou; Aggeliki Scrioubellou; Ioannis Tselentis; Antonios N Maniatis
Journal:  J Microbiol Methods       Date:  2003-10       Impact factor: 2.363

2.  Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Authors:  J Werngren; E Sturegård; P Juréen; K Ängeby; S Hoffner; T Schön
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

3.  Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Sami O Simons; Jakko van Ingen; Tridia van der Laan; Arnout Mulder; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

4.  Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Sheen; Miguel Quiliano; Andrés Gutierrez; Robert H Gilman
Journal:  Infect Genet Evol       Date:  2009-12-04       Impact factor: 3.342

5.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.

Authors:  A Scorpio; Y Zhang
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

6.  Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.

Authors:  Jirarut Jonmalung; Therdsak Prammananan; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  BMC Microbiol       Date:  2010-08-20       Impact factor: 3.605

7.  Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method.

Authors:  Claudio Scarparo; Paolo Ricordi; Giuliana Ruggiero; Paola Piccoli
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

8.  Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.

Authors:  Matsie Mphahlele; Heidi Syre; Håvard Valvatne; Ruth Stavrum; Turid Mannsåker; Tshilidzi Muthivhi; Karin Weyer; P Bernard Fourie; Harleen M S Grewal
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

9.  Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients.

Authors:  G E Louw; R M Warren; P R Donald; M B Murray; M Bosman; P D Van Helden; D B Young; T C Victor
Journal:  Int J Tuberc Lung Dis       Date:  2006-07       Impact factor: 2.373

10.  Tuberculosis drug resistance mutation database.

Authors:  Andreas Sandgren; Michael Strong; Preetika Muthukrishnan; Brian K Weiner; George M Church; Megan B Murray
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069
View more
  21 in total

1.  Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing.

Authors:  Melisa J Willby; Maria Wijkander; Joshua Havumaki; Kartee Johnson; Jim Werngren; Sven Hoffner; Claudia M Denkinger; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis.

Authors:  Grant Theron; Jason Limberis; Rouxjeane Venter; Liezel Smith; Elize Pietersen; Aliasgar Esmail; Greg Calligaro; Julian Te Riele; Marianna de Kock; Paul van Helden; Tawanda Gumbo; Taane G Clark; Kevin Fennelly; Robin Warren; Keertan Dheda
Journal:  Nat Med       Date:  2020-06-29       Impact factor: 53.440

3.  Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.

Authors:  Alice L den Hertog; Sandra Menting; Richard Pfeltz; Matthew Warns; Salman H Siddiqi; Richard M Anthony
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 4.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

5.  Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing.

Authors:  Kingsley King-Gee Tam; Kenneth Siu-Sing Leung; Gilman Kit-Hang Siu; Kwok-Chiu Chang; Samson Sai-Yin Wong; Pak-Leung Ho; Eunice Ka-Chun Leung; Wing-Cheong Yam
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

6.  Comprehensive Whole-Genome Sequencing and Reporting of Drug Resistance Profiles on Clinical Cases of Mycobacterium tuberculosis in New York State.

Authors:  Joseph Shea; Tanya A Halse; Pascal Lapierre; Matthew Shudt; Donna Kohlerschmidt; Patrick Van Roey; Ronald Limberger; Jill Taylor; Vincent Escuyer; Kimberlee A Musser
Journal:  J Clin Microbiol       Date:  2017-04-05       Impact factor: 5.948

7.  Optimising pyrazinamide for the treatment of tuberculosis.

Authors:  Nan Zhang; Radojka M Savic; Martin J Boeree; Charles A Peloquin; Marc Weiner; Norbert Heinrich; Erin Bliven-Sizemore; Patrick P J Phillips; Michael Hoelscher; William Whitworth; Glenn Morlock; James Posey; Jason E Stout; William Mac Kenzie; Robert Aarnoutse; Kelly E Dooley
Journal:  Eur Respir J       Date:  2021-07-20       Impact factor: 33.795

8.  Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Authors:  Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione
Journal:  Lancet Infect Dis       Date:  2016-07-07       Impact factor: 25.071

9.  Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.

Authors:  Glenn P Morlock; Frances C Tyrrell; Dorothy Baynham; Vincent E Escuyer; Nicole Green; Youngmi Kim; Patricia A Longley-Olson; Nicole Parrish; Courtney Pennington; Desmond Tan; Brett Austin; James E Posey
Journal:  Tuberc Res Treat       Date:  2017-11-08

10.  Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Authors:  L Rigouts; N Coeck; M Gumusboga; W B de Rijk; K J M Aung; M A Hossain; K Fissette; H L Rieder; C J Meehan; B C de Jong; A Van Deun
Journal:  J Antimicrob Chemother       Date:  2015-11-24       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.